NCT00090480View on ClinicalTrials.gov

Vaccine Treatment for Advanced Breast Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Breast Cancer
Interventions
BIOLOGICAL

HyperAcute - Breast cancer vaccine

Cells will be injected intradermally for four weeks for four cycles. Dosage will vary from 10 million to 100 million HAB cells.

Trial Locations (1)

50309

Medical Oncology Hematology Associates, Des Moines

Sponsors
All Listed Sponsors
lead

NewLink Genetics Corporation

INDUSTRY

NCT00090480 - Vaccine Treatment for Advanced Breast Cancer | Biotech Hunter | Biotech Hunter